Toll Free: 1-888-928-9744

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease (Retinal Disorder, Allergies), By Dosage Form (Eye Drops, Eye Solutions), By Product Type, And Segment Forecasts, 2019 - 2026

Published: Apr, 2019 | Pages: 190 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global ophthalmic drugs market size is expected to reach USD 43.1 billion by 2026 registering a CAGR of 4.5%, according to a new report by Grand View Research, Inc. Increased funding by public and private bodies for conducting research on ocular disorders and presence of strong emerging pipeline drugs are some of the factors responsible for the growth of ophthalmic therapeutics market. For instance, Shire and Parion Sciences collaborated to develop and commercialize P-321, which will be used in the treatment of dry eye diseases in adults. In addition, approval of novel products for the treatment of eye disorders is expected to propel the market.

For instance, in 2017, Nicox, received FDA approval of ZERVIATE (cetirizine ophthalmic solution) for treating ocular itching associated with allergic conjunctivitis. This product is the first topical ocular formulation of antihistamine.Key companies, such as Novartis AG, Bausch & Lomb Inc., and Pfizer, Inc., are involved in mergers & acquisitions to increase their market share. In 2017, Johnson & Johnson Services, Inc acquired Abbott Medical Optics, Inc. With this acquisition, all the products of Abbott Medical Optics, Inc. including consumer eye health, laser refractive surgery, and cataract surgery portfolio will be sold under the name of Johnson & Johnson.

Further key findings from the study suggest:

• Anti-VEGF agent led the market in 2018 and is anticipated to register the fastest CAGR of 7.9% from 2019 to 2026 owing to its wide usage in treating eye disorders, such as age-related macular degeneration and diabetic retinopathy

• Retinal disorder was estimated to be the largest segment and is considered to be the fastest-growing disease segment over the forecast period due to increasing prevalence of diabetic retinopathy

• Eye drops led the market in 2018 and is projected witness the highest CAGR due its cost-effectiveness as compared to other dosage forms

• Prescription drugs held the largest share in 2018 since it is considered to be more effective treatment

• OTC type is said to be the fastest-growing segment over the forecast period owing to easy accessibility of OTC drugs

• North America led the market in 2018 due to increasing demand for ophthalmic products for the treatment of dry eye and glaucoma

• Asia Pacific is anticipated to be the fastest growing regional market during the forecast period due to awareness programs conducted by various organizations and rising disposable income levels

• Some of the key companies in this market are Novartis AG; Bausch & Lomb, Inc.; Regeneron Pharmaceuticals, Inc.; Allergan PLC; Pfizer, Inc.; Bayer AG; Santen Pharmaceutical Co., Ltd.; and Genentech, Inc.
 Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market segmentation & scope
                     1.2. Market definition
                     1.3. Information procurement
                          1.3.1. Purchased database
                          1.3.2. GVR's internal database
                          1.3.3. Secondary sources & third party perspectives
                          1.3.4. Primary research
                     1.4. Information analysis
                          1.4.1. Data analysis models
                     1.5. Market formulation & data visualization
                     1.6. Data validation & publishing
Chapter 2. Executive Summary
                     2.1. Market Outlook 
                     2.2. Segment Outlook 
                     2.3. Competitive Insights
Chapter 3. Global Ophthalmic Drugs Market Variables, Trends & Scope
                     3.1. Ophthalmic Drugs Market Lineage outlook
                          3.1.1. Parent market outlook
                          3.1.2. Related/ancillary market outlook
                     3.2. Penetration & Growth Prospect Mapping
                     3.3. Pipeline Analysis
                     3.4. Cost Structure Analysis
                     3.5. Primary Research Analysis
                          3.5.1. Factors estimated to impact on market growth
                          3.5.2. Market scenario
                          3.5.3. Key KOL responses
                     3.6. Market Dynamics
                          3.6.1. Market Driver Analysis
                               3.6.1.1. Increasing incidence and prevalence of eye related disorders 
                               3.6.1.2. Increasing R&D pertaining to the development of novel drugs 
                               3.6.1.3. Presence of strong emerging pipeline drugs 
                               3.6.1.4. Increased funding from both public and private research organizations
                          3.6.2. Market Restraint Analysis
                               3.6.2.1. Loss of patent protection for blockbuster drugs 
                     3.7. Ophthalmic Drugs Market Analysis Tools
                          3.7.1. Industry Analysis - Porter's
                               3.7.1.1. Supplier Power: Low due to large number of manufacturers
                               3.7.1.2. Buyer Power: high due to increasing prevalence of eye related diseases
                               3.7.1.3. Substitution Threat: High due to presence external substitutes
                               3.7.1.4. Threat from new entrant: Moderate due to brand recognition of the existing players
                               3.7.1.5. Competitive rivalry: High due to rigorous competition among key players
                     3.8. PESTEL Analysis
                          3.8.1. Political Landscape
                          3.8.2. Environmental Landscape
                          3.8.3. Social Landscape
                          3.8.4. Technology Landscape
                          3.8.5. Legal Landscape
                     3.9. Major Deals & Strategic Alliances Analysis 
                          3.9.1. Joint Ventures 
                          3.9.2. Mergers & Acquisitions 
                          3.9.3. Licensing & Partnership 
                          3.9.4. Technology Collaborations 
                          3.9.5. Strategic Divestments 
Chapter 4. Ophthalmic Drugs Market - Competitive Analysis
                     4.1. Recent developments & impact analysis, by key market participants
                     4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
                     4.3. Public Companies
                          4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                          4.3.2. Company Market Share/Ranking, by region
                          4.3.3. Competitive Dashboard Analysis 
                          4.3.4. Market Differentiators 
                          4.3.5. Synergy Analysis: Major Deals & Strategic Alliances
                     4.4. Private Companies 
                          4.4.1. List of key emerging companies 
                          4.4.2. Regional network map
                          4.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis 
                     5.1. Definitions & Scope 
                     5.2. Drug class market share analysis, 2018 & 2026
                     5.3. Drug Class Dashboard 
                     5.4. Global Ophthalmic Drugs Market, by Drug Class, 2014 to 2026
                     5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                          5.5.1. Antiallergy
                               5.5.1.1. Antiallergy market, 2014 - 2026 (USD Million)
                          5.5.2. Anti-VEGF agents
                               5.5.2.1. Anti-VEGF market, 2014 - 2026 (USD Million)
                          5.5.3. Anti-inflammatory
                               5.5.3.1. Anti-inflammatory market, 2014 - 2026 (USD Million)
                               5.5.3.2. Nonsteroidal drugs
                                    5.5.3.2.1. Nonsteroidal market, 2014 - 2026 (USD Million)
                               5.5.3.3. Steroidal drugs
                                    5.5.3.3.1. Steroidal market, 2014 - 2026 (USD Million)
                          5.5.4. Antiglaucoma
                               5.5.4.1. Antiglaucoma market, 2014 - 2026 (USD Million)
                          5.5.5. Others
                               5.5.5.1. Others market, 2014 - 2026 (USD Million)
Chapter 6. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis
                     6.1. Definitions & Scope 
                     6.2. Disease market share analysis, 2018 & 2026
                     6.3. Disease Dashboard 
                     6.4. Global Ophthalmic Drugs Market, by Disease, 2014 to 2026
                     6.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                          6.5.1. Dry Eye
                               6.5.1.1. Dry eye market, 2014 - 2026 (USD Million)
                               6.5.1.2. Gels
                                    6.5.1.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.1.3. Eye solutions
                                    6.5.1.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.1.4. Capsules & Tablets
                                    6.5.1.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.1.5. Eye drops
                                    6.5.1.5.1. Eye drops market, 2014 - 2026(USD Million)
                               6.5.1.6. Ointments
                                    6.5.1.6.1. Ointments market, 2014 - 2026(USD Million)
                          6.5.2. Allergies
                               6.5.2.1. Allergies market, 2014 - 2026 (USD Million)
                               6.5.2.2. Gels
                                    6.5.2.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.2.3. Eye solutions
                                    6.5.2.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.2.4. Capsules & Tablets
                                    6.5.2.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.2.5. Eye drops
                                    6.5.2.5.1. Eye drops market, 2014 - 2026 (USD Million)
                               6.5.2.6. Ointments
                                    6.5.2.6.1. Ointments market, 2014 - 2026 (USD Million)
                          6.5.3. Glaucoma
                               6.5.3.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.3.2. Gels
                                    6.5.3.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.3.3. Eye solutions
                                    6.5.3.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.3.4. Capsules & Tablets
                                    6.5.3.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.3.5. Eye drops
                                    6.5.3.5.1. Eye drops market, 2014 - 2026 (USD Million)
                               6.5.3.6. Ointments
                                    6.5.3.6.1. Ointments market, 2014 - 2026 (USD Million)
                          6.5.4. Inflammation/ Infection
                               6.5.4.1. Inflammation/ Infection market, 2014 - 2026 (USD Million)
                               6.5.4.2. Gels
                                    6.5.4.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.4.3. Eye solutions
                                    6.5.4.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.4.4. Capsules & Tablets
                                    6.5.4.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.4.5. Eye drops
                                    6.5.4.5.1. Eye drops market, 2014 - 2026 (USD Million)
                               6.5.4.6. Ointments
                                    6.5.4.6.1. Ointments market, 2014 - 2026 (USD Million)
                          6.5.5. Retinal Disorders
                               6.5.5.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.5.2. Gels
                                    6.5.5.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.5.3. Eye solutions
                                    6.5.5.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.5.4. Capsules & Tablets
                                    6.5.5.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.5.5. Eye drops
                                    6.5.5.5.1. Eye drops market, 2014 - 2026 (USD Million)
                               6.5.5.6. Ointments
                                    6.5.5.6.1. Ointments market, 2014 - 2026 (USD Million)
                          6.5.6. Uveitis
                               6.5.6.1. Uveitis market, 2014 - 2026 (USD Million)
                               6.5.6.2. Gels
                                    6.5.6.2.1. Gels market, 2014 - 2026 (USD Million)
                               6.5.6.3. Eye solutions
                                    6.5.6.3.1. Eye solutions market, 2014 - 2026 (USD Million)
                               6.5.6.4. Capsules & Tablets
                                    6.5.6.4.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                               6.5.6.5. Eye drops
                                    6.5.6.5.1. Eye drops market, 2014 - 2026 (USD Million)
                               6.5.6.6. Ointments
                                    6.5.6.6.1. Ointments market, 2014 - 2026 (USD Million)
                          6.5.7. Others
Chapter 7. Ophthalmic Drugs Market: Dosage Form Estimates & Trend Analysis 
                     7.1. Definitions & Scope 
                     7.2. Dosage form market share analysis, 2018 & 2026
                     7.3. Dosage Form Dashboard 
                     7.4. Global Ophthalmic Drugs Market, by Dosage Form, 2014 to 2026
                     7.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                          7.5.1. Gels
                               7.5.1.1. Gels market, 2014 - 2026 (USD Million)
                          7.5.2. Eye solutions
                               7.5.2.1. Eye solutions market, 2014 - 2026 (USD Million)
                          7.5.3. Capsules & Tablets
                               7.5.3.1. Capsules & tablets market, 2014 - 2026 (USD Million)
                          7.5.4. Eye drops
                               7.5.4.1. Eye drops market, 2014 - 2026 (USD Million)
                          7.5.5. Ointments
                               7.5.5.1. Ointments market, 2014 - 2026 (USD Million)
Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis 
                     8.1. Definitions & Scope 
                     8.2. Product type market share analysis, 2018 & 2026
                     8.3. Product Type Form Dashboard 
                     8.4. Global Ophthalmic Drugs Market, by Product Type, 2014 to 2026
                     8.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                          8.5.1. Prescription drugs
                               8.5.1.1. Prescription drugs market, 2014 - 2026 (USD Million)
                          8.5.2. OTC drugs
                               8.5.2.1. OTC drugs market, 2014 - 2026 (USD Million)
Chapter 9. Ophthalmic Drugs Market: Regional Estimates & Trend analysis, by type, end-use and end-use by type 
                     9.1. Regional Market Snapshot 
                     9.2. Regional Market Share and Leading Players, 2018
                          9.2.1. North America
                          9.2.2. Europe
                          9.2.3. Asia Pacific
                          9.2.4. Latin America
                          9.2.5. Middle East & Africa
                     9.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                          9.3.1. North America 
                          9.3.2. Europe
                          9.3.3. Asia Pacific
                          9.3.4. Latin America
                          9.3.5. Middle East & Africa
                     9.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                          9.4.1. North America 
                               9.4.1.1. North America anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.1.2. U.S.
                                    9.4.1.2.1. U.S. anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.1.3. Canada
                                    9.4.1.3.1. Canada anti-infective agents market, 2014 - 2026 (USD Million)
                          9.4.2. Europe
                               9.4.2.1. Europe anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.2. U.K.
                                    9.4.2.2.1. U.K. anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.3. Germany
                                    9.4.2.3.1. Germany anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.4. Spain
                                    9.4.2.4.1. Spain anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.5. France
                                    9.4.2.5.1. France anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.6. Italy
                                    9.4.2.6.1. Italy anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.2.7. Russia
                                    9.4.2.7.1. Russia anti-infective agents market, 2014 - 2026 (USD Million)
                          9.4.3. Asia Pacific
                               9.4.3.1. Asia Pacific anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.2. China
                                    9.4.3.2.1. China anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.3. Japan
                                    9.4.3.3.1. Japan anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.4. India
                                    9.4.3.4.1. India anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.5. South Korea
                                    9.4.3.5.1. South Korea anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.6. Singapore
                                    9.4.3.6.1. Singapore anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.3.7. Australia
                                    9.4.3.7.1. Australia anti-infective agents market, 2014 - 2026 (USD Million)
                          9.4.4. Latin America
                               9.4.4.1. Latin America anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.4.2. Brazil
                                    9.4.4.2.1. Brazil anti-infectives agents market, 2014 - 2026 (USD Million)
                               9.4.4.3. Mexico
                                    9.4.4.3.1. Mexico anti-infectives agents market, 2014 - 2026 (USD Million)
                               9.4.4.4. Argentina
                                    9.4.4.4.1. Argentina anti-infective agents market, 2014 - 2026 (USD Million)
                          9.4.5. Middle East Africa
                               9.4.5.1. MEA anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.5.2. South Africa
                                    9.4.5.2.1. South Africa anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.5.3. Saudi Arabia
                                    9.4.5.3.1. Saudi Arabia anti-infective agents market, 2014 - 2026 (USD Million)
                               9.4.5.4. UAE
                                    9.4.5.4.1. UAE anti-infective agents market, 2014 - 2026 (USD Million)
Chapter 10. Company Profiles
                     10.1. Strategic Framework
                          10.1.1. Novartis AG (Alcon)
                               10.1.1.1. Company overview
                               10.1.1.2. Financial framework
                               10.1.1.3. Product benchmarking
                               10.1.1.4. Geographic footprint
                               10.1.1.5. Strategic initiatives
                          10.1.2. Johnson & Johnson Services Inc.
                               10.1.2.1. Company overview
                               10.1.2.2. Financial framework
                               10.1.2.3. Product benchmarking
                               10.1.2.4. Geographic footprint
                               10.1.2.5. Strategic initiatives
                          10.1.3. Bausch & Lomb Incorporated
                               10.1.3.1. Company overview
                               10.1.3.2. Financial framework
                               10.1.3.3. Product benchmarking
                               10.1.3.4. Geographic footprint
                               10.1.3.5. Strategic initiatives
                          10.1.4. Merck Sharp & Dohme Corp.
                               10.1.4.1. Company overview
                               10.1.4.2. Financial framework
                               10.1.4.3. Product benchmarking
                               10.1.4.4. Geographic footprint
                               10.1.4.5. Strategic initiatives
                          10.1.5. Regeneron Pharmaceuticals Inc.
                               10.1.5.1. Company overview
                               10.1.5.2. Financial framework
                               10.1.5.3. Product benchmarking
                               10.1.5.4. Geographic footprint
                               10.1.5.5. Strategic initiatives
                          10.1.6. ALLERGAN
                               10.1.6.1. Company overview
                               10.1.6.2. Financial framework
                               10.1.6.3. Product benchmarking
                               10.1.6.4. Geographic footprint
                               10.1.6.5. Strategic initiatives
                          10.1.7. Pfizer, Inc.
                               10.1.7.1. Company overview
                               10.1.7.2. Financial framework
                               10.1.7.3. Product benchmarking
                               10.1.7.4. Geographic footprint
                               10.1.7.5. Strategic initiatives
                          10.1.8. Bausch Health
                               10.1.8.1. Company overview
                               10.1.8.2. Financial framework
                               10.1.8.3. Product benchmarking
                               10.1.8.4. Geographic footprint
                               10.1.8.5. Strategic initiatives
                          10.1.9. Bayer AG
                               10.1.9.1. Company overview
                               10.1.9.2. Financial framework
                               10.1.9.3. Product benchmarking
                               10.1.9.4. Geographic footprint
                               10.1.9.5. Strategic initiatives
                          10.1.10. Santen Pharmaceutical Co., Ltd
                               10.1.10.1. Company overview
                               10.1.10.2. Financial framework
                               10.1.10.3. Product benchmarking
                               10.1.10.4. Geographic footprint
                               10.1.10.5. Strategic initiatives
                          10.1.11. Genentech, Inc.
                               10.1.11.1. Company overview
                               10.1.11.2. Financial framework
                               10.1.11.3. Product benchmarking
                               10.1.11.4. Geographic footprint
                               10.1.11.5. Strategic initiatives
List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 3 North America Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 4 North America Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 5 North America Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 6 North America Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 7 North America Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 8 North America Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 9 North America Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 10 North America Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 11 North America Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 12 U.S. Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 13 U.S. Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 14 U.S. Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 15 U.S. Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 16 U.S. Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 17 U.S. Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 18 U.S. Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 19 U.S. Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 20 U.S. Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 21 U.S. Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 22 Canada Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 23 Canada Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 24 Canada Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 25 Canada Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 26 Canada Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 27 Canada Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 28 Canada Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 29 Canada Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 30 Canada Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 31 Canada Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 32 Europe Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 33 Europe Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 34 Europe Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 35 Europe Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 36 Europe Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 37 Europe Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 38 Europe Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 39 Europe Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 40 Europe Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 41 Europe Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 42 U.K. Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 43 U.K. Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 44 U.K. Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 45 U.K. Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 46 U.K. Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 47 U.K. Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 48 U.K. Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 49 U.K. Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 50 U.K. Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 51 U.K. Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 52 Germany Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 53 Germany Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 54 Germany Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 56 Germany Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 57 Germany Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 58 Germany Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 59 Germany Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 60 Germany Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 61 Germany Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 62 Germany Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 63 France Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 64 France Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 65 France Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 66 France Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 67 France Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 68 France Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 69 France Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 70 France Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 71 France Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 72 France Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 73 Italy Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 74 Italy Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 75 Italy Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 76 Italy Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 77 Italy Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 78 Italy Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 79 Italy Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 80 Italy Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 81 Italy Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 82 Italy Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 83 Spain Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 84 Spain Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 85 Spain Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 86 Spain Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 87 Spain Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 88 Spain Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 89 Spain Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 90 Spain Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 91 Spain Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 92 Spain Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 93 Russia Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 94 Russia Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 95 Russia Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 96 Russia Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 97 Russia Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 98 Russia Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 99 Russia Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 100 Russia Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 101 Russia Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 102 Russia Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 103 Asia Pacific Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 104 Asia Pacific Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 105 Asia Pacific Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 106 Asia Pacific Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 107 Asia Pacific Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 108 Asia Pacific Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 109 Asia Pacific Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 110 Asia Pacific Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 111 Asia Pacific Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 112 Asia Pacific Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 113 Japan Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 114 Japan Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 115 Japan Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 116 Japan Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 117 Japan Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 118 Japan Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 119 Japan Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 120 Japan Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 121 Japan Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 122 Japan Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 123 China Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 124 China Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 125 China Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 126 China Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 127 China Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 128 China Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 129 China Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 130 China Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 131 China Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 132 China Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 133 India Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 134 India Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 135 India Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 136 India Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 137 India Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 138 India Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 139 India Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 140 India Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 141 India Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 142 India Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 143 South Korea Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 144 South Korea Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 145 South Korea Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 146 South Korea Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 147 South Korea Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 148 South Korea Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 149 South Korea Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 150 South Korea Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 151 South Korea Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 152 South Korea Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 153 Australia Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 154 Australia Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 155 Australia Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 156 Australia Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 157 Australia Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 158 Australia Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 159 Australia Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 160 Australia Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 161 Australia Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 162 Australia Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 163 Singapore Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 164 Singapore Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 165 Singapore Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 166 Singapore Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 167 Singapore Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 168 Singapore Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 169 Singapore Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 170 Singapore Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 171 Singapore Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 172 Singapore Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 173 Latin America Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 174 Latin America Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 175 Latin America Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 176 Latin America Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 177 Latin America Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 178 Latin America Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 180 Latin America Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 181 Latin America Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 182 Latin America Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 183 Latin America Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 184 Brazil Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 185 Brazil Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 186 Brazil Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 187 Brazil Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 188 Brazil Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 189 Brazil Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 190 Brazil Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 191 Brazil Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 192 Brazil Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 193 Brazil Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 194 Mexico Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 195 Mexico Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 196 Mexico Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 197 Mexico Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 198 Mexico Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 199 Mexico Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 200 Mexico Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 201 Mexico Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 202 Mexico Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 203 Mexico Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 204 Argentina Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 205 Argentina Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 206 Argentina Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 207 Argentina Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 208 Argentina Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 209 Argentina Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 210 Argentina Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 211 Argentina Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 212 Argentina Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 213 Argentina Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 214 MEA Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 215 MEA Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 216 MEA Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 217 MEA Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 218 MEA Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 219 MEA Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 220 MEA Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 221 MEA Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 222 MEA Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 223 MEA Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 224 South Africa Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 225 South Africa Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 226 South Africa Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 227 South Africa Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 228 South Africa Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 229 South Africa Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 230 South Africa Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 231 South Africa Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 232 South Africa Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 233 South Africa Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 234 UAE Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 235 UAE Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 236 UAE Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 237 UAE Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 238 UAE Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 239 UAE Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 240 UAE Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 241 UAE Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 242 UAE Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 243 UAE Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)
TABLE 244 Saudi Arabia Ophthalmic Drugs Market, by Drug Class, 2014 - 2026 (USD Million)
TABLE 245 Saudi Arabia Ophthalmic Drugs Market, by Disease, 2014 - 2026 (USD Million)
TABLE 246 Saudi Arabia Dry Eye Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 247 Saudi Arabia Allergies Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 248 Saudi Arabia Glaucoma Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 249 Saudi Arabia Inflammation/ Infection Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 250 Saudi Arabia Retinal Disorders Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 251 Saudi Arabia Uveitis Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 252 Saudi Arabia Ophthalmic Drugs Market, by Dosage Form, 2014 - 2026 (USD Million)
TABLE 253 Saudi Arabia Ophthalmic Drugs End-use Market, by Product Type, 2014 - 2026 (USD Million)

 


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global ophthalmic drugs- Key market driver analysis
FIG. 7 Global ophthalmic drugs market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Factors estimated to impact on market growth
FIG. 10 Global ophthalmic drugs market - Porter's analysis
FIG. 11 Global ophthalmic drugs market - PESTEL analysis
FIG. 12 Global ophthalmic drugs market drug class outlook key takeaways
FIG. 13 Global ophthalmic drugs market: Drug Class movement analysis
FIG. 14 Antiallergy market estimates, 2014 - 2026 (USD Million)
FIG 15 Anti-VEGF agents market estimates, 2014 - 2026 (USD Million)
FIG. 16 Anti-inflammatory market estimates, 2014 - 2026 (USD Million)
FIG 17 Non-steroidal drugs market estimates, 2014 - 2026 (USD Million)
FIG. 18 Steroidal market estimates, 2014 - 2026 (USD Million)
FIG. 19 Antiglaucoma market estimates, 2014 - 2026 (USD Million)
FIG. 20 Others market estimates, 2014 - 2026 (USD Million)
FIG. 21 Global ophthalmic drugs market disease outlook key takeaways
FIG. 22 Global ophthalmic drugs market: Disease movement analysis
FIG. 23 Dry eye market estimates, 2014 - 2026 (USD Million)
FIG. 24 Allergies market estimates, 2014 - 2026 (USD Million)
FIG. 25 Glaucoma market estimates, 2014 - 2026 (USD Million)
FIG. 26 Inflammation/ Infection market estimates, 2014 - 2026 (USD Million)
FIG. 27 Retinal disorders market estimates, 2014 - 2026 (USD Million)
FIG. 28 Uveitis market estimates, 2014 - 2026 (USD Million)
FIG. 29 Others market estimates, 2014 - 2026 (USD Million)
FIG. 30 Global ophthalmic drugs market dosage form outlook key takeaways
FIG. 31 Global ophthalmic drugs market: Dosage Form movement analysis
FIG. 32 Gels market estimates, 2014 - 2026 (USD Million)
FIG. 33 Eye solutions market estimates, 2014 - 2026 (USD Million)
FIG. 34 Capsules & tablets market estimates, 2014 - 2026 (USD Million)
FIG. 35 Eye drops market estimates, 2014 - 2026 (USD Million)
FIG. 36 Ointments market estimates, 2014 - 2026 (USD Million)
FIG. 37 Global ophthalmic drugs market product type outlook key takeaways
FIG. 38 Global ophthalmic drugs market: Product type movement analysis
FIG. 39 Prescription drugs market estimates, 2014 - 2026 (USD Million)
FIG. 40 OTC drugs market estimates, 2014 - 2026 (USD Million)
FIG. 41 Regional market place: Key takeaways
FIG. 42 Global ophthalmic drugs market: Regional movement analysis
FIG. 43 North America ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 44 U.S. ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 45 Canada ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 46 Europe ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 47 U.K. ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 48 Germany ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 49 France ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 50 Spain ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 51 Italy ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 52 Russia ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 53 Asia Pacific ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 54 Japan ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 55 China ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 56 India ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 57 South Korea ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 58 Singapore ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 59 Australia ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 60 Latin America ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 61 Brazil ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 62 Mexico ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 63 Argentina ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 64 MEA ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 65 South Africa ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 66 UAE market, 2014 - 2026 (USD Million)
FIG. 67 Saudi Arabia ophthalmic drugs market, 2014 - 2026 (USD Million)
FIG. 68 Strategy framework

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $4950
Multi User - US $5950
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify